Rhythm Pharmaceuticals Receives EC Authorization For Obesity Therapy
The European Commission has granted authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity. This marks the first therapy of its kind to receive both FDA approval and EC authorization.
Topics
Developing
- 863d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 863d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 863d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 863d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Mastodon
“Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide)— First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity — European Commission grants authorization…”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade